Prior treatment with anti-PD-1 or anti-PD-L1 therapeutic antibody, or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (NCI Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:\r\n* Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization\r\n* No history of severe immune-related adverse effects (CTCAE Grade 3 and 4) from anti-CTLA-4
Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose, and no history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Patients who have received prior treatment with anti-CTLA-4 antibody may be enrolled, provided the following requirements are met:\r\n* > 6 weeks from the last dose\r\n* No history of severe immune-related adverse effects from anti-CTLA-4 antibody (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Prior therapy with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents.\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose.\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4).
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents; but patients who have received prior treatment with anti·CTLA-4 may be enrolled, provided the following requirements are met: (1) minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose; (2) no history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology for Cancer Adverse Effects CTCAE] grade 3 and 4)
(Atezolizumab-related exclusion) Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents a) Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3 and 4)
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Patients who have received prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody, or pathway -targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and >6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents. Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4).
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Note:\r\n** Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n*** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n*** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] grade 3 and 4)
Has received prior therapy with an anti-CTLA4 agent
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE grade 3 and 4)
Patients who have received prior treatment with anti?CTLA-4 may be enrolled, provided the following requirements are met:\r\n* Minimum of 12 weeks from the first dose of anti?CTLA-4 and > 6 weeks from the last dose\r\n* No history of severe immune-related adverse effects from anti?CTLA-4 (CTCAE grade 3 and 4)
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-cytotoxic T lymphocyte-associated antigen (CTLA-4) may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last\r\ndose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] common terminology criteria for adverse events [CTCAE] grade 3 and 4)
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents or eribulin\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 5.0)
Prior anti-PD-L1 therapies are excluded\r\n* Patients who have received prior treatment with immunotherapy including anti-PD-1 anti-CTLA-4 may be enrolled, provided that there was no history of severe immune-related adverse effects (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] grade 3 and 4)
No history of severe immune-related adverse effects from anti CTLA 4 (CTCAE Grade 3 and 4)
Prior treatment with an anti-CTLA-4 agent